Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Commingling

the parties have agreed to established guidelines and procedures relating to proposed license arrangements to be entered into by TPL involving the MMP Portfolio patents and one or more other patents within TPL’s portfolio that is not an MMP

Do we share in the licensing revenues of the non-MMP revenues or just the expenses? What does this mean for us? Did we negotiate something of value for the future or just give him permission to commingle based on his promise to us of better oversight. If you can't beat them join them.

1
Oct 17, 2011 07:23PM
Share
New Message
Please login to post a reply